ETERNA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.96 USD | -8.41% |
|
-9.26% | +9.19% |
| Mar. 15 | North American Morning Briefing : Inflation -2- | DJ |
| Mar. 14 | Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | - | Sales 2023 | 0.07 | Capitalization | 9.71M |
|---|---|---|---|---|---|
| Net income 2022 | -24M | Net income 2023 | -21M | EV / Sales 2022 | - |
| Net cash position 2022 | 10.26M | Net Debt 2023 | 34.27M | EV / Sales 2023 | 646,758,000 x |
| P/E ratio 2022 |
-0.4
x | P/E ratio 2023 |
-0.44
x | Employees | 8 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.69% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -8.41% | ||
| 1 week | -9.26% | ||
| Current month | -18.33% | ||
| 1 month | -17.65% | ||
| 3 months | +13.30% | ||
| 6 months | +15.29% | ||
| Current year | +9.19% |
1 week
1.94
2.24
1 month
1.942.50
Current year
1.332.57
1 year
0.843.45
3 years
0.841 613.40
5 years
0.841 613.40
10 years
0.841 613.40
| Managers | Title | Age | Since |
|---|---|---|---|
Sanjeev Luther
CEO | Chief Executive Officer | 62 | Dec. 31 |
Sandra Gurrola
DFI | Director of Finance/CFO | 57 | 21-06-20 |
Megan Yung
LAW | General Counsel | - | 23-05-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Bristol
CHM | Chairman | 77 | 23-10-29 |
William Wexler
BRD | Director/Board Member | 65 | 22-06-06 |
Dorothy Clarke
BRD | Director/Board Member | 59 | 23-08-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 1.96 | -8.41% | 9,867 |
| 24-04-22 | 2.14 | -0.47% | 5,610 |
| 24-04-19 | 2.15 | 0.00% | 3,924 |
| 24-04-18 | 2.15 | 0.00% | 4,767 |
| 24-04-17 | 2.15 | -0.46% | 2,666 |
Delayed Quote Nasdaq, April 23, 2024 at 04:30 pm EDT
More quotes
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.19% | 10.6M | |
| +3.13% | 43.43B | |
| +48.49% | 41.69B | |
| +8.49% | 41.31B | |
| -10.82% | 27.14B | |
| +8.26% | 25.28B | |
| -23.69% | 18.47B | |
| +1.58% | 12.33B | |
| +32.83% | 12.59B | |
| +6.63% | 11.03B |
- Stock Market
- Equities
- ERNA Stock
